Navigation Links
CNS Response, Inc: rEEG(R) Research to be Presented at 38th National Council Conference

COSTA MESA, Calif., May 2 /PRNewswire-FirstCall/ -- CNS Response, Inc. (OTC Bulletin Board: CNSO) announced today that Dr. Daniel Hoffman, M.D., Chief Medical Officer, CNS Response, Dr. Henry Harbin, M.D., Board Member, CNS Response and Dr. James Greenblatt, M.D., Chief Medical Officer, Walden Behavioral Care Inpatient Psychiatry and Eating Disorder Programs, will deliver a presentation on Referenced EEG-guided personalized medicine and its potential for treating patients with behavioral disorders at the National Council for Community Behavioral Healthcare 38th National Council Conference.

The presentation, titled "Personalized Medicine in Psychiatry: Using EEG-Guided Medication Decisions," will offer an overview of the science and current results of using Quantitative EEG's to predict psychotropic medication responses. Specific research from CNS Response's Referenced EEG (rEEG) and Aspect Medical's BRITE study will be reviewed, including the use of rEEG for treatment refractory Eating Disorder Patients.

rEEG uses traditional electroencephalography (EEG) in conjunction with a normative database and a proprietary clinical (symptomatic) database to identify medication classes most likely to be needed and medications within those classes with the most probable treatment potential for each patient. The BRITE study predicts whether the SSRI's tested will alter certain EEG variables in order to predict a positive response within a few days of taking the medication. Implications for the future practice of psychiatry, including efficiency, cost savings, and effectiveness in treatment resistant populations, will be discussed.

The presentation, which is part of the Emerging Treatment Technologies track, will occur on Friday, May 2, 2008 from 3:45 p.m. to 5:15 p.m., EDT. The 38th National Council Conference is taking place in Boston, MA, at the Marriott Copley Place from May 1-3, 2008.

Further information on National Council for Community Behavioral Healthcare and the 38th National Council Conference can be found at

About CNS Response

CNS Response is a life-sciences data company whose patented system provides treatment guidance to psychiatrists and other physicians for patients with behavioral (mental or addictive) disorders. This technology allows CNS Response to create and provide simple reports ("rEEG(R) Reports") that specifically guide physicians to treatment strategies based on the patient's own physiology.

rEEG(R) utilizes traditional electroencephalography (EEG) in conjunction with a normative database and a proprietary clinical (symptomatic) database to identify the following: (1) medication classes most likely to be needed; and (2) medications within these classes with the most probable treatment potential for each patient. Reports are provided to physicians in a relationship analogous to that of a reference laboratory. Prospective, retrospective and field studies of treatment-resistant patients have reported treatment success of 70% or greater in managed care, outpatient psychiatric and residential substance abuse clinical settings.

In addition to providing analytical support to physicians, CNS Response is also an aid to pharmaceutical developers, who can use rEEG to (1) stratify study populations to improve the success of FDA clinical trials; (2) provide insight on effective therapeutic dosing of investigational drugs; (3) identify additional indications for psychiatric medications; (4) provide insight into effective drug combinations; and (5) discover opportunities for decision analytics and support. In addition to these applications, CNS Response continues to investigate the use of rEEG analysis for development of proprietary pharmaceutical opportunities.

Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995

Except for the historical information contained herein, the matters discussed are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. These statements involve risks and uncertainties as set forth in the Company's filings with the Securities and Exchange Commission. These risks and uncertainties could cause actual results to differ materially from any forward-looking statements made herein.


Investor Relations:

Sara Ephraim

(646) 536-7002


Jason Rando / Jennifer Saunders

(646) 536-7033 / 7011

SOURCE CNS Response, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. CNS Response, Inc. Appoints George C. Carpenter IV to Position of President
2. CNS Response, Inc. Modifies rEEG(SM) Trial Protocol for Treatment-Resistant Depression Study
3. CNS Response, Inc. Names Henry T. Harbin, MD to Board of Directors
4. Bacterial toxin closes gate on immune response, Penn researchers discover
5. CNS Response, Inc. Enters Agreement to Introduce rEEG(R) Platform to Managed Behavioral Health Organization
6. Stanford researchers find culprit in aging muscles that heal poorly
7. Children of depressed moms do better when dad is involved, SLU researcher finds
8. UCLA researchers identify markers that may predict diabetes in still-healthy people
9. Mayo Clinic researchers discover new diagnostic test for detecting infection in prosthetic joints
10. New research shows how chronic stress worsens neurodegenerative disease course
11. New research explores newborn in-hospital weight loss
Post Your Comments:
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is World Sickle Cell ... pain and the benefits of holistic treatments, Serenity Recovery Center of Marne, ... Cell Disease. , Sickle Cell Disease (SCD) is a disorder of the red blood ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... Sessions in Dallas that it will receive two significant new grants to support ... as PHA marked its 25th anniversary by recognizing patients, medical professionals and scientists ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. Amanda Cheng, an ... Dr. Cheng has extensive experience with all areas of orthodontics, including robotic Suresmile ... orthodontics. , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. It can ...
(Date:6/24/2016)... ... 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join ... wage raise to $12 an hour by 2020 and then adjusting it yearly to increase ... of the minimum wage, assure the wage floor does not erode again, and make future ...
(Date:6/24/2016)... Georgia (PRWEB) , ... June 24, 2016 , ... ... awards today at the Clinical Decision Making in Emergency Medicine conference in Ponte ... have authored journal articles published in Emergency Medicine Practice and Pediatric ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... , June 23, 2016 Research and ... News Issue 52" report to their offering. ... influenza treatment creates a favourable commercial environment for MedImmune to ... patient base that will serve to drive considerable growth for ... would serve to cap sales considerably, but development is still ...
(Date:6/23/2016)... , June 23, 2016  Astellas today announced the establishment of Astellas Farma Colombia (AFC), a new affiliate ... in Latin America . ... ... ... ...
(Date:6/23/2016)... June 23, 2016 Research and ... Procedure Volumes: Global Analysis (United States, China, Japan, Brazil, ... report to their offering. ... for healthcare business planners, provides surgical procedure volume data ... trends with an in-depth analysis of growth drivers and ...
Breaking Medicine Technology: